PATENT CLAIM ANALYSIS

Application Number: 16079059
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to methods of treating, preventing or managing intestinal fibrosis by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of intestinal fibrosis using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-β (TGF-β) levels, α-Smooth Muscle Actin (a-SMA) levels, and/or phosphorylated Mothers Against Decapentaplegic Homolog 3 (p-SMAD3) levels.

Claim (Index 33):
The method of  claim 26  or  claim 28 , wherein if the level of TGF-\u03b2 is above normal levels of TGF-\u03b2, then administering to the patient a subsequent dose that is greater than the initial dose, or, if the level of TGF-\u03b2 is below normal levels of TGF-\u03b2 then administering to the patient a subsequent dose that is smaller than the initial dose.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 96.0
- Lexical Diversity: 1.55556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15063077', '16046389', '12854558', '14144029', '12264058']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7755201217027247
- 35 USC 102 Novelty (BERT): 0.5398918949677524
- Combined Prediction Score: 0.7519572990292275
- Mean Citation Score: 335.939554
- Max Citation Score: 336.40283
- Similarity Product: 149.45956524353088

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test